People who stop taking GLP-1 medications like Ozempic and Wegovy started to regain weight in a short amount of time, ...

Experts highlight interventions to support muscle and nutrient preservation during GLP-1 treatment and offer practical ...

When glucagon-like peptide-1 receptor agonists (GLP-1s) like semaglutide (Wegovy) and liraglutide (Saxenda) were approved for ...

The appetite-suppressing medications reduce consumption of processed and sugary foods, creating new risks and opportunities.

The hormonal changes of menopause can make the weight gain more resistant to traditional diet and lifestyle changes. But ...

The demand for GLP-1 medications is only increasing. As employees seek better health benefits, employers who act now will set ...

Those projections of reduced spending were reflected in a survey released in December by data analytics firm Numerator that ...

The "try and fail" language is flawed when weight loss is used as the primary measure of success with lifestyle interventions ...

More and more research indicates that GLP-1 analogues can have a blunting effect on addictions like drugs and alcohol. Drug ...

Pediatric endocrinologist Dr. Casey Berman says GLP-1s may help children reduce their risk of developing serious health ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.